Cancer Cause and Prevention Research Grants (Assistance Listing 93.393)

National Institutes of Health · Up to $375K

This NIH R15 (REAP) award funds small-scale research and student research experiences at health-professional and graduate schools that receive limited NIH funding, with a minimal-risk clinical trial required. Eligibility is restricted to degree-granting institutions that have received no more than $6 million per year of NIH support in 4 of the last 7 years; foreign organizations are not eligible. Awards reach up to about $375,000. The NIH-funding cap and institution-type limits make eligibility narrow, so verify your institution qualifies.

National Institutes of Health · Amount varies

This NIH STTR program (R41/R42) funds U.S. small businesses that partner with a nonprofit research institution to move scientific innovations toward commercialization. Eligibility is limited to U.S. small business concerns as defined by the SBA, and foreign organizations are not eligible. No award amount is listed.

National Institutes of Health · Amount varies

This NIH SBIR Phase IIB award is restricted to U.S. small business concerns that have previously received an NIH SBIR or STTR Phase II award; it bridges the gap between Phase II and commercialization for later-stage R&D. Only one such award is allowed per project, and applications must be submitted within the first six due dates after the Phase II budget period ends, so it is narrow and limited to existing grantees. Foreign organizations are not eligible to apply.

National Institutes of Health · Amount varies

This NIH SBIR/STTR Commercialization Readiness Pilot (CRP) is restricted to U.S. small business concerns (as defined by the SBA) and helps move NIH-funded SBIR/STTR projects from late-stage development toward commercialization. It supports later-stage R&D and technical assistance such as replication studies, IND/IDE-enabling work, clinical studies, manufacturing scale-up, and regulatory support, and a significant portion may be subcontracted. Foreign organizations are not eligible to apply.

National Institutes of Health · Amount varies

This NIH/CDC/FDA SBIR program (R43/R44) funds U.S. small businesses developing scientific innovations toward commercial products through feasibility and R&D studies. Eligibility is limited to U.S. small business concerns as defined by the SBA, and foreign organizations are not eligible. No award amount is listed.

National Institutes of Health · $50K–$600K

This NIH (NCI) U24 cooperative agreement funds the continued operation and maintenance of established, widely-adopted informatics tools and resources used across cancer research; clinical trials are optional. Applicants must demonstrate that their resource is already widely used and has had significant impact, so it targets teams maintaining existing informatics infrastructure rather than new projects. Foreign organizations and the foreign components of U.S. organizations are eligible to apply, and foreign components are allowed. Awards range from about $50,000 to $600,000.

National Institutes of Health · Amount varies

This NIH/National Cancer Institute award funds NCORP Research Bases that serve as research hubs designing and running multi-institution cancer control, prevention, and care-delivery clinical trials. It is aimed at established research organizations with the scientific, statistical, and data-management infrastructure to lead a community oncology research network. Foreign organizations and foreign components of U.S. organizations are not eligible. Eligibility details are in the NOFO, so review Section III before applying.

National Institutes of Health · $50K–$600K

This NIH (NCI) U24 cooperative agreement funds advanced development and enhancement of emerging cancer informatics technologies that have passed initial prototyping but are not yet widely adopted; clinical trials are optional. It targets teams with a promising informatics tool ready for further development and broader impact, so eligibility is effectively oriented toward established research/informatics groups. Foreign organizations and the foreign components of U.S. organizations are eligible to apply, and foreign components are allowed. Awards range from about $50,000 to $600,000.

National Institutes of Health · Amount varies

This NIH/NCI program (UG1) funds NCORP Academic Community Sites, which are consortia led by an academic center with affiliated community hospitals and oncology practices, to broaden participation in cancer control, prevention, treatment, and care-delivery studies. Eligibility centers on academic medical centers with the infrastructure to support accrual across affiliates; foreign organizations and foreign components are not eligible. No award amount is stated. This is restricted to qualifying academic-led community research consortia, not general applicants.

National Institutes of Health · Amount varies

This NIH/NCI program (UG1) funds NCORP Community Sites, which are healthcare systems or consortia of community hospitals, oncology practices, public hospitals, or health centers that broaden participation in cancer control, prevention, treatment, and care-delivery research. Eligibility centers on healthcare systems and community-based oncology networks; foreign organizations and foreign components are not eligible. No award amount is stated. This is aimed at community healthcare organizations participating in NCORP, not individuals or general nonprofits.

National Institutes of Health · $50K–$300K

This NIH/NCI U01 funds early-stage development of informatics tools and technologies that improve how cancer research data is acquired, managed, analyzed, and shared. Eligibility is described in the funding notice, and foreign organizations and their U.S. components may apply. Awards run from about $50,000 up to $300,000. Projects must engage end users and show clear potential to advance cancer research, so the scope is specific.

National Institutes of Health · Amount varies

This NIH/NCI (U01) cooperative agreement funds research using cancer epidemiology cohort studies to address gaps in cancer causes and survivorship, including cohort infrastructure, continued follow-up, and data/biospecimen sharing. It is aimed at research institutions running or analyzing large epidemiologic cohorts. Eligibility is comparatively open for NIH: foreign organizations and foreign components of U.S. organizations are eligible to apply, though foreign components as defined by NIH are not allowed. Clinical trials are not permitted under this NOFO.

National Institutes of Health · Up to $500K

This NIH (R01) Bioengineering Research Grant funds multidisciplinary projects that apply engineering approaches to biomedical, clinical, or translational problems, with a stated budget up to about $500,000. It supports clinical trials that validate performance but excludes Phase III trials, conventional non-translational trials, and commercial production. Eligibility is relatively broad for an NIH grant: both foreign organizations and foreign components of U.S. organizations are eligible to apply, though foreign components (as defined by NIH) are not allowed.

National Institutes of Health · Amount varies

This NIH opportunity provides administrative supplements only to organizations that already hold an active, eligible NIH grant or cooperative agreement, to cover unforeseen increased costs within the scope of the existing project. New applicants without a current NIH award cannot use it. Funding is not guaranteed, and applicants must discuss requests with the awarding Institute's staff before submitting; foreign organizations may apply only consistent with the existing parent award.

National Institutes of Health · Amount varies

Open to U.S. universities, research institutions, nonprofits, and certain government/tribal organizations; foreign organizations are not eligible. This NIH R01 supports early-stage investigators pursuing a new research direction, and applications must include no preliminary data. Award size follows standard R01 limits; aimed at researchers early in their independent careers.

National Institutes of Health · Amount varies

For existing NCI early-stage-investigator MERIT (R37) awardees applying to extend their award, submitted through their U.S. or eligible institution. The extension provides up to seven years of total support across two segments, giving early-career cancer researchers extra time before a renewal. Eligibility is narrow — limited to current ESI MERIT grantees.

National Institutes of Health · Amount varies

The NIH parent Exploratory/Developmental Research Grant (R21, clinical trial required) supports early-stage research projects with at least one clinical trial, aligned with participating NIH institutes' missions. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. No specific award amount is stated. The clinical-trial requirement makes this best suited to research institutions with trial capacity.

National Institutes of Health · Amount varies

The NIH parent Exploratory/Developmental Research Grant (R21, clinical trial not allowed) supports early-stage, higher-risk research projects that may lead to breakthroughs or novel methods. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. No specific award amount is stated. This is an exploratory research mechanism aimed at research institutions.

National Institutes of Health · Amount varies

The NIH parent Research Project Grant (R01, clinical trial not allowed) supports investigator-initiated research projects aligned with participating NIH institutes' missions, excluding clinical trials. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. No specific award amount is stated. This is a core NIH research mechanism aimed at research institutions.

National Institutes of Health · Amount varies

This NIH (NCI, U01) program funds research on how preanalytical variability in handling tumor tissue, blood, and other biospecimens affects clinically relevant biomarkers, to support standardization of biopsy handling and clinical assay development. Eligible applicants are research organizations including universities, colleges, government and tribal entities, and faith- or community-based organizations; it targets established research teams, not individuals or general nonprofits. Award amounts are not specified. Confirm program-specific eligibility in the full announcement.

National Institutes of Health · Amount varies

An NIH/NCI exploratory/developmental bioengineering research grant (EBRG, R21, clinical trial not allowed) funding feasibility-stage projects that develop new capabilities or improvements for biomedical, pre-clinical, or clinical research and care. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. No specific award amount is stated. This is a bioengineering research mechanism aimed at research institutions.

National Institutes of Health · Amount varies

An NIH/NCI exploratory/developmental bioengineering research grant (EBRG, R21, clinical trial optional) funding feasibility-stage projects that develop new capabilities or improvements for biomedical, pre-clinical, or clinical research and care. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. No specific award amount is stated. This is a bioengineering research mechanism aimed at research institutions.

National Institutes of Health · Up to $375K

The REAP program funds small-scale research at health professional and graduate schools that haven't been major recipients of NIH support, while giving students hands-on research experience. Eligibility is limited to institutions awarding NIH-relevant degrees that received under $6 million per year in NIH support in 4 of the last 7 years — a specific financial threshold worth checking before applying. Awards go up to $375,000.

National Institutes of Health · Up to $375K

An NIH Academic Research Enhancement Award (AREA/R15) for undergraduate-focused institutions that do not receive substantial NIH funding, supporting small-scale biomedical research with undergraduate involvement. Eligibility is narrow: institutions must award baccalaureate science degrees and have received no more than about $6 million per year of NIH support in 4 of the last 7 years; foreign organizations are not eligible. The award is capped at about $375,000. This is restricted to qualifying lower-NIH-funded undergraduate institutions.

National Institutes of Health · Amount varies

An NIH research project grant (R01, clinical trials optional) supporting population-based research on how work and occupation influence health outcomes among populations with health disparities. Eligible applicants are domestic institutions such as universities, tribal governments, and community-based organizations; foreign organizations, foreign components of U.S. organizations, and foreign components are not eligible. No specific award amount is stated. This suits research institutions conducting population health-disparities research.

National Institutes of Health · Amount varies

This NIH/NCI U01 funds cancer etiology and early-detection biomarker research that must use the NCI-sponsored PLCO Screening Trial biospecimen resource. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, tribal governments, foreign organizations, and U.S. territories; it targets research organizations, not individuals. No award amount is specified. Projects that do not use PLCO biospecimens will not be funded, which narrows eligibility significantly.

National Institutes of Health · Amount varies

This NIH AREA (R15) award funds small-scale research at undergraduate-focused institutions that receive limited NIH funding, emphasizing undergraduate research experiences; a minimal-risk clinical trial is required. Eligible institutions must grant baccalaureate science degrees and have received no more than about $6 million per year of NIH support in 4 of the last 7 years; foreign organizations are not eligible. No specific award amount is stated.

National Institutes of Health · Up to $200K

NIH (NCI) R21 funding for secondary analysis and integration of existing datasets to study cancer risk and related outcomes; clinical trials are not allowed under this notice. Intended for research institutions and investigators, including minority-serving and tribal colleges. The listed maximum is about $200,000. This is institution-based research funding using existing data, not suited to individuals or general nonprofits.

National Institutes of Health · Up to $350K

This NIH/NCI R01 grant funds secondary analysis and integration of existing datasets to study cancer risk and related outcomes such as survival and treatment response. It is a research grant for universities, research institutions, and similar eligible organizations, including various minority-serving institutions, tribal entities, and foreign organizations. The award maximum is about $350,000. Eligibility is oriented toward research institutions rather than nonprofits, small businesses, or individuals broadly, and applicants typically need access to relevant existing data.

National Institutes of Health · Amount varies

An NIH/NCI research project grant (R01, clinical trial not allowed) funding basic, mechanistic research into the biological and genetic causes of cancer health disparities. A broad set of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. No specific award amount is stated. This is a basic-science oncology mechanism aimed at research institutions building expertise in cancer disparities.

National Institutes of Health · Amount varies

This NIH R01 funds preclinical and patient-based research into how incretin mimetics (such as GLP-1 agents) affect cancer risk. Eligible applicants include universities, research institutions, tribal and community organizations, and foreign organizations; a clinical trial is optional. It requires established research capacity in this area. No specific award amount is stated.

National Institutes of Health · Amount varies

This NIH R21 funds preclinical and patient-based research into how incretin mimetics (such as GLP-1 agents) affect cancer risk; no clinical trial is allowed. Eligible applicants include universities, research institutions, tribal and community organizations, and foreign organizations. It requires research capacity in this area. No specific award amount is stated.

National Institutes of Health · Amount varies

This NIH (R21) opportunity funds basic, mechanistic research into the biological and genetic causes of cancer health disparities, including new methods, models, and secondary data analyses. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is stated.

National Institutes of Health · Amount varies

This NIH/National Cancer Institute R01 supports investigator-initiated clinical trials in cancer prevention and control, such as early detection, screening, and survivorship research. Typical applicants are universities, research institutions, hospitals, tribal organizations, and government and community organizations; foreign organizations are listed among eligible applicants here. A qualifying clinical trial is required, so it is geared toward established research teams. No specific award amount is stated.

National Institutes of Health · Up to $500K

This NIH/National Cancer Institute R01 funds investigator-initiated early-phase (Phase 0, I, II) clinical trials for cancer diagnosis and treatment; a clinical trial is required. Eligible applicants include universities, research institutions, hospitals, tribal and community organizations, and foreign organizations. The maximum award is just under $500,000. It is geared toward established clinical research teams.

National Institutes of Health · Amount varies

Open to U.S. and foreign research institutions, universities, nonprofits, and certain government/tribal organizations. This NIH/NCI R21 funds early-stage, exploratory research on cancer control — prevention behaviors, screening, etiology, and novel methods. Award size follows standard R21 limits.

National Institutes of Health · Amount varies

This NIH (R01) opportunity supports investigator-initiated research in cancer control and population sciences, including epidemiology, survivorship, behavioral interventions, and health-data science. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is given.

National Institutes of Health · Up to $500K

An NIH/NCI research project grant (R01) funding projects that integrate medical imaging with fluid-based (liquid biopsy) tumor monitoring during cancer therapy. Eligible applicants are domestic institutions such as universities, tribal governments, and community-based organizations; foreign organizations and foreign components are not eligible. The award is capped at about $500,000. This is an oncology research mechanism aimed at research institutions, not individuals or general nonprofits.

National Institutes of Health · Up to $499K

This NIH/National Cancer Institute R01 award funds projects to improve the reliability and translational usefulness of mammalian cancer and tumor models, with no clinical trials allowed. It is aimed at research institutions and investigators, with a broad list of eligible U.S. organization types. The stated maximum award is about $499,000. Applications are submitted through eligible organizations rather than by individuals.

National Institutes of Health · Amount varies

This NIH (R01) opportunity funds collaborative research on chronic or delayed adverse effects of cancer therapies and mechanism-based interventions to prevent or reduce them. It is aimed at research and academic institutions, not individuals or typical nonprofits/small businesses. No specific award amount is stated.

National Institutes of Health · Amount varies

This NIH (R61/R33) phased opportunity funds mechanistic research to advance precision probiotic therapies, beginning with an exploratory phase to identify person-specific factors and a second phase to test them in animal models or human subjects, over a combined period of up to five years. Eligible applicants are U.S. research organizations including universities, government and tribal entities, and faith- or community-based organizations; foreign organizations and non-U.S. components are not eligible to apply, though some foreign components are allowed. Transition between phases depends on meeting milestones. It is intended for established research teams, not individuals or general nonprofits. Award amounts are not specified.

National Institutes of Health · Amount varies

This NIH (R33) opportunity funds mechanistic research to advance precision probiotic therapies by characterizing person-specific factors that affect probiotic responses, using animal models or human subjects. Eligible applicants are U.S. research organizations including universities, government and tribal entities, and faith- or community-based organizations; foreign organizations and non-U.S. components are not eligible to apply, though some foreign components are allowed. It expects supportive preliminary data and is intended for established research teams, not individuals or general nonprofits. Award amounts are not specified.

National Institutes of Health · Amount varies

This NIH (R13) program supports conferences and scientific meetings relevant to public health and the missions of participating NIH institutes. Eligible applicants are U.S. research and education organizations including universities, government and tribal entities, and faith- or community-based organizations; foreign organizations and non-U.S. components are not eligible to apply, though some foreign components are allowed. Note that R13 conference support typically requires advance permission from the funding institute before applying. It is aimed at organizations hosting scientific conferences, not individuals. Award amounts are not specified.

National Institutes of Health · Up to $350K

This NIH HEAL Initiative R61/R33 funds early translational drug-discovery research toward non-addictive pain therapeutics, including assay development, screening, and initial characterization of candidate agents; no clinical trial is allowed. Eligible applicants include universities, research institutions, and tribal and community organizations, but foreign organizations are not eligible to apply. The maximum award is about $350,000. It requires drug-discovery research capacity.

National Institutes of Health · Up to $500K

This NCI (R01) opportunity funds investigator-initiated studies on the mechanisms by which bariatric surgery affects cancer risk. It is intended for research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $500,000.

National Institutes of Health · Amount varies

An NIH/NCI exploratory grant (R21, clinical trial not allowed) funding proof-of-concept studies on the mechanisms by which bariatric surgery affects cancer risk. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. No specific award amount is stated. Projects must address feasibility not already established in the literature, so this suits research institutions with relevant preliminary direction.

National Institutes of Health · Amount varies

An NIH research project grant (R01, clinical trial optional) funding multi-level health-care research to improve care for older adults from populations that experience health disparities. Eligible applicants are domestic institutions such as universities, tribal governments, and community-based organizations; foreign organizations and foreign components are not eligible. No specific award amount is stated. This suits research institutions focused on aging and health-disparities care research.

National Institutes of Health · Amount varies

This NIH mechanism is narrowly limited to organizations that already hold specific NIH grants and need to transfer an award due to a change in organizational status (successor-in-interest). It is an administrative prior-approval request, not a new funding opportunity, and approval of the transfer is not guaranteed. Only current NIH grantee organizations should use it; it does not apply to individuals, new applicants, or general nonprofits. No award amount applies.

National Institutes of Health · Amount varies

This NIH mechanism is narrowly limited to organizations that already hold specific types of NIH grants and need to transfer an existing award to a new recipient institution (a change of recipient organization). It is an administrative prior-approval request, not a new funding opportunity, and there is no guarantee a transfer will be approved. Only current NIH grantee organizations should apply; it does not apply to individuals, new applicants, or general nonprofits. No award amount applies.

National Institutes of Health · Up to $375K

This NIH R15 (AREA) award supports small-scale research at undergraduate-focused institutions that receive limited NIH funding, with a required clinical trial. Eligibility is restricted to institutions that award baccalaureate science degrees and have received no more than $6 million/year of NIH support in 4 of the last 7 years; foreign organizations are not eligible to apply. The maximum award is about $375,000. This is narrowly targeted at less-research-intensive degree-granting institutions.